BJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis

Size: px
Start display at page:

Download "BJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis"

Transcription

1 BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and James M. McKiernan Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA Accepted for publication 27 July 2011 Study Type Therapy (case series) Level of Evidence 4 OBJECTIVE To examine the effect of time from last positive biopsy to surgery on clinical outcomes in men with localized prostate cancer undergoing radical prostatectomy (RP). PATIENTS AND METHODS We conducted a retrospective review of 2739 men who underwent RP between 1990 and 2009 at our institution. Clinical and pathological features were compared between men undergoing RP 60, and > 90 days from the time of prostate biopsy. A Cox proportional hazards model was used to analyse the association between clinical features and surgical delay with biochemical progression. Biochemical recurrence (BCR)-free rates were assessed using the Kaplan Meier method. What s known on the subject? and What does the study add? For patients electing surgical treatment, the question of the effect of surgical delay on clinical outcomes in prostate cancer is controversial. In this study we examined the effect of delay from diagnosis to surgery on outcomes in men with localized prostate cancer and found no association between time to surgery and risk of biochemical recurrence, even for patients with longer delays and high-risk disease. Men with localized prostate cancer can be reassured that reasonable delays in treatment will not influence disease outcomes. RESULTS Of the 1568 men meeting the inclusion criteria, 1098 (70%), 303 (19.3%) and 167 (10.7%) had a delay of 60, and >90 days, respectively, between biopsy and RP. A delay of > 60 days was not associated with adverse pathological findings at surgery. The 5-year survival rate was similar among the three groups (78 85%, P = 0.11). In a multivariate Cox model, men with higher PSA levels, clinical stages, Gleason sums, and those of African-American race were all at higher risk for developing BCR. A delay to surgery of > 60 days was not associated with worse biochemical outcomes in a univariate and multivariate model. CONCLUSIONS A delay of > 60 days is not associated with adverse pathological outcomes in men with localized prostate cancer, nor does it correlate with worse BCR-free survival. Patients can be assured that delaying treatment while considering therapeutic options will not adversely affect their outcomes. KEYWORDS time factors, prostatic neoplasm/surgery, prostatic neoplasm/pathology, disease progression INTRODUCTION Patients diagnosed with prostate cancer must navigate an increasingly complicated web of decisions about treatment, including if and when radical prostatectomy (RP) is appropriate. While patient anxiety may often lead to a short interval between diagnosis and surgery, other logistic factors such as health insurance coverage, medical or personal problems, and surgeon or operating room availability may also cause delays in surgery of variable length [1 ]. As localized prostate cancer is generally accepted to have an indolent course, such delays tend to be tolerated by physicians and patients alike; however, the question of whether treatment delays negatively impact patient outcomes is controversial, and the oncology literature varies with respect to different cancers. Delaying cystectomy is well known to adversely impact survival among patients with bladder cancer [2 ] and early treatment may improve survival for head and neck and lung cancers as well [3,4 ]. Treatment delays do not appear to affect survival for either breast or colon cancer [5,6 ], but the current literature provides conflicting information regarding delayed RP for prostate cancer [1,7 11 ]. Pretreatment prognostic factors including serum PSA, Gleason score, AJCC staging, and 2011 BJU INTERNATIONAL 110, doi: /j x x 211

2 KORETS ET AL. preoperative risk models have been used to predict response to therapeutic intervention and patient outcomes. It is therefore not surprising that these same clinical markers have also been used by physicians, less formally, to help determine the urgency of treatment. In the present study, we examine the effect of delay from diagnosis to surgery on outcomes in men with localized prostate cancer and analyse the impact of the delay across well described patient risk categories. PATIENTS AND METHODS STUDY POPULATION Using the Institutional Review Boardapproved Columbia University Urologic Oncology Database, we conducted a retrospective review of all patients treated with RP by five high-volume surgeons between 1990 and This query identified 2739 patients. Time to surgery (TTS) was defined as the period between the most recent positive prostate biopsy and RP. Of these patients, we excluded patients who had received neoadjuvant androgen deprivation ( n = 41), adjuvant ( n = 59) androgen deprivation or immediate adjuvant external beam radiation ( n = 45), who had unknown biopsy dates ( n = 615), and who had < 12 months of follow-up after RP ( n = 411). Records of patients with surgical delays of > 180 days were reviewed to ensure that none of the patients included in the analysis had been placed on active surveillance with delayed curative intervention protocols. Biochemical recurrence (BCR) was defined as a single serum PSA level of 0.2 ng/ml at least 21 days after RP [12 ]. STATISTICAL ANALYSIS Men were divided into three groups based on surgical delay that has been previously reported in the literature: Group 1 ( 60 days), Group 2 (61 90 days), Group 3 ( 91 days) [8,10 ]. The clinicopathological characteristics were compared among the groups using ANOVA for continuous variables and the chi-squared for categorical variables. Age at diagnosis and logarithmically transformed preoperative PSA levels were examined as continuous variables. Patient race/ethnicity (Caucasian vs. African-American vs. Hispanic vs. other), year of surgery ( vs TABLE 1 Clinical and pathological characteristics Group 1: 60 days Group 2: days Group 3: >90 daysp No. of patients (%) 1098 (70) 303 (19.3) 167 (10.7) Race/Ethnicity, n (%) White 767 (69.9) 228 (75.3) 124 (74.3) Black 118 (10.7) 21 (6.9) 14 (8.4) Hispanic 87 (7.9) 22 (7.3) 8 (4.8) Other 126 (11.5) 32 (10.5) 21 (12.5) Median age (IQR) 60 (55, 66) 61 (56, 66) 61 (57, 66) Year of surgery, n (%) (5.8) 37 (12.2) 23 (13.8) (28.9) 109 (36.0) 44 (26.4) (32.2) 79 (26.0) 53 (31.7) (33.1) 78 (25.8) 47 (28.1) Mean preoperative PSA (IQR) 5.7 (4.3, 8.0) 6.2 (4.7, 8.7) 6.2 (4.5, 8.2) Clinical stage, n (%) ct1 680 (61.9) 186 (61.4) 112 (67.1) ct2 410 (37.4) 112 (36.9) 55 (32.9) ct3 8 (0.7) 5 (1.7) 0 (0) Biopsy Gleason sum, n (%) < (50.0) 159 (53.0) 101 (61.2) (37.8) 112 (37.3) 57 (34.6) > (12.2) 29 (9.7) 7 (4.2) D Amico Risk-Group, n (%) Low 351 (34.1) 109 (37.1) 73 (47.7) Intermediate 554 (53.8) 158 (53.7) 72 (47.1) High 125 (12.1) 27 (9.2) 8 (5.2) Surgical approach Open 884 (80.5) 264 (87.1) 140 (83.8) Robot-assisted 214 (19.5) 39 (12.9) 27 (16.2) Median follow-up (IQR) 57 (27, 86) 65 (38, 108) 64 (37, 99) vs vs ), clinical stage (T1 vs. T2 vs. T3), Gleason sum ( < 7 vs. = 7 vs. >7), D Amico risk group [13 ] and surgical approach were examined as categorical variables. The odds ratios (ORs) of adverse pathological findings at surgery (Gleason sum upgrade, positive surgical margins, extracapsular extension, seminal vesicle invasion and positive node status) were calculated for all TTS groups using logistical regression. Linear regression modelling was used to determine the effect of TTS as a continuous variable on BCR. Cox proportional hazards model was used to analyse the effect of age, race/ethnicity, PSA, clinical stage, biopsy Gleason sum, year of surgery, surgical approach and TTS on risk of BCR. BCR-free survival was compared across the TTS groups using the Kaplan Meier method and the log-rank test. For all tests, two-sided P values < 0.05 were considered to indicate statistical significance. All analyses were conducted using S TATA version 11.0 (StataCorp, College Station, TX, USA). RESULTS In all, 1568 patients met the inclusion criteria for the study. The median age of patients at the time of diagnostic biopsy was 60 years (interquartile range [IQR ] : 56, 66). The median (range) time to RP among the entire study cohort was 45 (36 847) days (IQR: 42, 65). A total of 1098 patients (70.0%) had surgery within 60 days, 303 patients (19.3%) waited days and 167 patients (10.7%) delayed surgery for >90 days. Forty-one patients (2.6%) experienced a delay of >180 days. Table 1 shows the clinical and pathological characteristics of the three study groups, stratified by TTS. Men with lower biopsy Gleason grades and low-risk D Amico stratification experienced BJU INTERNATIONAL

3 DELAYED SURGERY AND RADICAL PROSTATECTOMY OUTCOMES TABLE 2 Odds ratio of adverse pathological findings at surgery 60 days days (95% CI) > 90 days (95% CI) P Gleason sum upgrade 1.00 (ref) 1.11 ( ) 1.08 ( ) 0.48, 0.96 Positive surgical margin 1.00 (ref) 1.13 ( ) 1.06 ( ) 0.38, 0.86 Extracapsular extension 1.00 (ref) 1.03 ( ) 0.95 ( ) 0.84, 0.07 Seminal vesicle invasion 1.00 (ref) 0.91 ( ) 0.91 ( ) 0.49, 0.45 Positive lymph nodes 1.00 (ref) 0.87 ( ) 0.99 ( ) 0.53, 0.68 TABLE 3 Cox proportional hazards model of risk of BCR Univariate Multivariate HR CI P HR CI P Age Race/Ethnicity White ref ref Black Hispanic Other Preoperative PSA < <0.001 Clinical stage ct1 ref ref ct ct Biopsy Gleason < 7 ref ref < <0.001 > < <0.001 Year of surgery ref D Amico Risk-Group Low ref ref Intermediate < <0.001 High < Minimally invasive surgery No ref Yes TTS Group 60 days ref ref days >90 days longer delays than men from higher-risk groups or those with more advanced Gleason sum findings. Compared with men treated in the 1990s, men treated during the last 10 years of our study period were less likely to experience delays > 60 days ( P = 0.004). Furthermore, men electing to have robot-assisted prostatectomy experienced shorter delays to surgery than men undergoing open RP ( P = 0.02). The median follow-up time after surgery was 64 months (IQR: 30, 93). During this time 275/1568 (17.5%) men experienced BCR. The ORs of adverse findings at prostatectomy across the TTS groups are shown in Table 2. No significant association was observed between TTS and adverse pathological findings including: Gleason sum upgrade, positive surgical margins, extracapsular extension, seminal vesicle invasion and positive lymph nodes. To examine if treatment delay led to a higher risk of disease progression, we used a linear regression model to analyse TTS as a continuous variable. In this model, TTS was not associated with BCR (hazard ratio [ HR ] : 1.02, 95% CI: ; P = 0.29). On univariate analysis older age, non-caucasian race, higher preoperative PSA level, advanced clinical stage and biopsy Gleason grade were all associated with increased risk of BCR (Table 3 ). A significant association was not found between year of surgery, surgical approach or TTS group and BCR. In a multivariate model comprised of all variables that showed a significant association with BCR on univariate analysis, older age (HR: 1.02), higher PSA (HR: 1.53), intermediate and high D Amico risk groups (HR: 1.89, 1.93), clinical stage >ct1 (HR: 1.41, 3.59), biopsy Gleason sum >6 (HR: 1.95, 4.42), and African-American race (HR: 1.93) were all significantly associated with BCR. Delay to prostatectomy of >60 days was not associated with higher rates of clinical progression. When examining only a group of men at high risk of BCR by D Amico criteria, no differences in recurrence rates were observed between the three TTS groups according to the log-rank test ( P = 0.479). Kaplan Meier analysis showed a 5-year BCR-free survival of 80% in men who underwent RP < 60 days after last positive biopsy. The results were similar for men who underwent RP within days, and >90 days of last positive biopsy (78% and 85%, respectively; P = 0.11 [Fig. 1 ] ). DISCUSSION Patients initially diagnosed with prostate cancer face an ever-growing number of decisions about how best to proceed with their treatment. In this setting, logistical factors such as insurance coverage, personal conflicts and surgeon and operating room availability, as well as patients desire to explore multiple treatment options, are likely to cause delays in therapy. Choosing an appropriate treatment for prostate cancer has become even more complicated in recent years, as the dramatic increase in prevalence of PSA screening has led to a 2011 BJU INTERNATIONAL 213

4 KORETS ET AL. stage migration toward lower-risk disease among newly diagnosed patients [14 ]. This dynamic has allowed many patients to elect to have delayed treatment or active surveillance protocols in an effort to prevent overtreatment and the morbidities associated with aggressive therapeutic interventions [15,16 ]. Nevertheless, the characteristics of early lesions are not well understood, and the safety of active surveillance protocols has not been completely assured. The optimum management for these early-stage lesions of uncertain biological potential, therefore, remains controversial. Biochemical Recurrence-Free Survival Time, months Log-rank: P = <60 days days >90 days FIG. 1. Kaplan Meier estimates of BCR rates, stratified by time from last positive biopsy to surgery. Given this uncertainty, attempting to understand the prognostic significance of delays in surgical treatment becomes essential to providing patients with the best chance of a cure without unnecessarily compromising quality of life. The benefits of early definitive treatment for prostate cancer have been suggested by reports of improved stage- and grade-specific progression-free survival rates after RP in the PSA era [ 17 ] ; however, the impact of delayed time to all treatment varies in the oncology literature. Early treatment appears to confer a survival advantage for bladder, head and neck and lung cancers [2 4 ], but delays in treatment are not associated with a decline in overall survival rates for either breast or colon cancer [5,6 ]. Meanwhile, the effect of delaying radiation therapy has been shown to affect outcomes in prostate cancer patients with high-risk but not intermediate- or low-risk disease [18 ]. For patients choosing surgical treatment, the question of the effect of surgical delay on clinical outcomes in prostate cancer remains uncertain, with studies to date showing inconsistent results [1,7 11 ]. Based on a study population of 645 Canadian patients, Nam et al. [7 ] found an insignificant increase in risk of BCR among patients who had a delay of >3 months between diagnostic biopsy and RP (OR 1.58, P = 0.09). The authors also found improved 10-year recurrence-free survival rates for patients who underwent early surgery vs those who had delayed intervention (74.6% vs 61.3%, P = 0.05). Similarly, Freedland et al. [8 ] explored the clinical outcomes of 895 patients in a low-risk group (PSA < 10 and Gleason score 6). While the authors found no association between surgical delay and negative pathological outcomes (high grade disease, positive surgical margins or extraprostatic extension), longer delays were associated with an increased risk of BCR (log rank P = 0.01). Controlling for other risk factors, surgical delay was associated with a significantly higher risk of BCR (RR 2.73, P = 0.002) for patients who waited >180 days before surgery. There have also been a number of studies that detected no such relationship between delayed surgical intervention and prostate cancer outcomes. Van den Bergh et al. [1 ] examined 227 men with low-risk disease who underwent either immediate RP (mean [SD ] time to RP 0.5 [ 0.2 ] years) or expectant management followed by RP (mean [ SD ] time to RP 2.6 [ 2.0 ] years), and found no significant difference in risk of negative pathological features (extracapsular extension, positive margins or tumour size) between the two groups. The authors did find a decreased rate of BCR among the immediate RP cohort (9% at 10 years, vs. 35% for delayed RP), but these results were not significant (log-rank P = 0.689). In an earlier series, Vickers et al. [19 ] reported on the effect of treatment delay on BCR for 3149 patients with clinically localized prostate cancer treated within 1 year of diagnosis [19 ]. In a multivariate model controlling for stage, Gleason score and PSA, the authors found that a delay of 1 year had no significant effect on risk of BCR at 3, 5, 8 or 10 years of follow-up ( P > 0.2 for all). Boorjian et al. [10 ] also reported on this same series of 3149 patients, and found that time to RP, treated as either a continuous or categorical variable (divided at 90 days), had no significant effect on risk of subsequent BCR. Notably, time to RP was still not an independent predictor of BCR after stratifying by preoperative risk, such that delays of > 90 days did not adversely affect outcome for patients with a nomogrampredicted risk of BCR of 40% ( P = 0.548) [9 ]. In two other large series, Khan et al. [ 10 ] showed no association between time to RP and risk of BCR for surgical delays of 151 days, and Graefen et al. [11 ] also reported no association between time to surgery (continuous variable) and BCR, even for patients with high-grade disease. In the present study, we found no association between TTS and risk of BCR, even for patients with longer delays or higher-risk disease. These data suggest that nearly all patients with localized prostate cancer can be reassured that wait times of reasonable length will not affect their chances of cure after definitive treatment. Furthermore, our results support the continued use of deferred treatment or active surveillance protocols for appropriately selected patients with low-risk disease [20 ]. While our findings are consistent with a number of previous studies [1,9 11 ], the reason for variation among reports in the literature is not immediately clear. Common thinking would suggest that the indolent nature of progression for localized prostate cancer is such that surgical delays which may seem quite long (up to 150 days in some reports [10 ] ) are actually relatively short compared with the disease course, and thus do not allow for clinical progression to occur before definitive treatment BJU INTERNATIONAL

5 DELAYED SURGERY AND RADICAL PROSTATECTOMY OUTCOMES Unfortunately this logic cannot explain why some studies have reported worse outcomes among patients who delayed treatment, particularly since these studies [7,8 ] used similar time cut-off points (for defining early vs. delayed treatment) to studies that found no association between surgical delay and adverse outcomes [1,9 11 ]. Although the studies have attempted to control for potential confounders such as age, clinical or tumour stage and Gleason score between groups, all reports to date have been retrospective, so it is possible that unmeasurable factors affecting time to RP, such as surgeons clinical judgment, may have biased the results of these studies. As such, further study in prospective trials would be needed to assess more definitively the effects of treatment delay. It is well known, however, that some patients with clinically localized prostate cancer, particularly those with intermediateor high-risk disease, will eventually progress to metastatic disease if left untreated [21 ]. We must assume, therefore, that for these patients, there is a point after which it is no longer safe to delay definitive therapy. This reasoning is particularly relevant to African-American men, who are known to be at greater risk of dying from prostate cancer [22 ]. An interesting finding in the present study is that, on multivariate analysis, African-American race continued to be an independent predictor of BCR while controlling for all other covariates. This finding is consistent with earlier results from our centre, which showed that African-American men are significantly more likely than Caucasian or Hispanic men to have an adverse change in their nomogrampredicted risk of BCR after RP [23 ]. These results suggest that apart from standard measures of preoperative risk such as clinical stage, Gleason score, and PSA, there may be inherent differences in tumour biology that portend worse outcomes for African-American patients. The biology of localized prostate cancer also presents a potential research area that would help to address questions of the effect of treatment delay. Early tumour biology is not completely understood, but patients with longer TTS may have higher rates of micrometastases as a result of delays in the removal of the primary tumour. One study detected tumour cells in bone marrow using reverse transcriptase polymerase chain reaction and immunocytochemistry in 56% of patients with organ-confined disease [24 ]. Micrometastases may be a result of, or accompanied by, molecular changes that are, at least theoretically, more likely to accumulate with delay in removal of the primary lesion. Although they are still being defined, multiple gene alterations have been associated with both pathological features of high-risk prostate cancer and also with disease-specific mortality [25,26 ]. The present study was not designed to detect either micrometastases or molecular changes caused by delays in definitive surgical treatment, but further research may help to incorporate these factors into the clinical management of men with prostate cancer. The present study has several limitations that warrant a brief discussion. First, as it is a retrospective study, the findings could be confounded by selection bias, as well as by variables that were not included in the analysis. Additionally, as our institution is a tertiary academic centre, a significant number of patients that are treated have had their biopsies performed elsewhere, with the slides re-reviewed by our institution s uropathologist. The exact date of the biopsy could not be verified in 611 (22%) patients, and as a result they were excluded from the analysis. Given that detection of death from prostate cancer requires long follow-up times, this study used a number of surrogate endpoints, including pathological findings, a post-rp nomogram and BCR, to predict negative clinical outcomes associated with disease. These have all been previously validated as surrogate outcomes in prostate cancer [27 29 ], but we must assume that they are not perfect predictors of diseasespecific mortality. Despite these limitations, the present study represents one of the largest series to date examining the effect of delayed RP. As such, it supports the existing evidence that delays in surgical treatment have no adverse effects on long-term cancer control for men with localized prostate cancer. In conclusion, in this study of 1568 men with prostate cancer treated with RP, we found no association between delayed TTS and risk of either BCR or adverse pathological outcome. These data suggests that men with localized prostate cancer can be reassured that reasonable delays in treatment will not influence disease outcomes. CONFLICT OF INTEREST None declared. REFERENCES 1 van den Bergh RC, Steyerberg EW, Khatami A et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010 ; 116 : Kulkarni GS, Urbach DR, Austin PC, Fleshner NE, Laupacis A. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009 ; 182 : Robertson C, Robertson AG, Hendry JH et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 1998 ; 40 : O Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 2000 ; 12 : Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 1999 ; 353 : Roncoroni L, Pietra N, Violi V, Sarli L, Choua O, Peracchia A. Delay in the diagnosis and outcome of colorectal cancer: a prospective study. Eur J Surg Oncol 1999 ; 25 : Nam RK, Jewett MA, Krahn MD et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 2003 ; 10 : Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 2006 ; 175 : ; discussion Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA. Does the time from biopsy to surgery affect biochemical recurrence 2011 BJU INTERNATIONAL 215

6 KORETS ET AL. after radical prostatectomy? BJU Int 2005 ; 96 : Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 2004 ; 172 : Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer impact on prognosis? Eur Urol 2005 ; 47 : Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostatespecific antigen. Urology 2003 ; 61 : D Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002 ; 95 : Littrup PJ. Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994 ; 74 : Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007 ; 109 : Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008 ; 358 : Desireddi NV, Roehl KA, Loeb S et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007 ; 70 : Nguyen PL, Whittington R, Koo S et al. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer 2005 ; 103 : Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006 ; 106 : Shappley WV 3rd, Kenfield SA, Kasperzyk JL et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009 ; 27 : Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 ; 293 : Jayadevappa R, Chhatre S, Johnson JC, Malkowicz SB. Variation in quality of care among older men with localized prostate cancer. Cancer 2010 ; [Epub ahead of print] 23 Laudano MA, Badani KK, McCann TR et al. Significant change in predicted risk of biochemical recurrence after radical prostatectomy more common in black than in white men. Urology 2009 ; 74 : Melchior SW, Corey E, Ellis WJ et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997 ; 3 : Pressinotti NC, Klocker H, Schafer G et al. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer 2009 ; 8 : Reid AH, Attard G, Ambroisine L et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010 ; 102 : Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 ; 23 : Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 ; 294 : Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 2007 ; 110 : Correspondence: James M. McKiernan, Department of Urology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, Herbert Irving Pavilion 11th Floor, New York, NY 10032, USA. jmm23@columbia.edu Abbreviations : RP, radical prostatectomy ; BCR, biochemical recurrence ; TTS, time to surgery ; OR, odds ratio ; IQR, interquartile range ; HR, hazard ratio BJU INTERNATIONAL

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c. . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

three after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].

three after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1]. . 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor

More information

Predictive factors of late biochemical recurrence after radical prostatectomy

Predictive factors of late biochemical recurrence after radical prostatectomy JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original

More information

Correspondence should be addressed to Taha Numan Yıkılmaz;

Correspondence should be addressed to Taha Numan Yıkılmaz; Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score

More information

Information Content of Five Nomograms for Outcomes in Prostate Cancer

Information Content of Five Nomograms for Outcomes in Prostate Cancer Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:

More information

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN

More information

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

More information

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory

More information

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,

More information

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence

More information

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on

More information

Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes

Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*

More information

Chapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract

Chapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal

More information

in 32%, T2c in 16% and T3 in 2% of patients.

in 32%, T2c in 16% and T3 in 2% of patients. BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson

More information

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory

More information

ORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1

ORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1 (2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue

More information

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:

1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7  Abstract: ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database

Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,

More information

Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System

Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2

More information

Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting

Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:

More information

Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy

Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh

More information

Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy

Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy 2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,

More information

Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2

Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2 Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent

More information

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy

Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer

External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

Providing Treatment Information for Prostate Cancer Patients

Providing Treatment Information for Prostate Cancer Patients Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact

More information

PROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?

PROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER? Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT

More information

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.

More information

Key words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality

Key words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

Department of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Department of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16

More information

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,

More information

Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion

Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in

More information

Prostate Cancer Treatment for Economically Disadvantaged Men

Prostate Cancer Treatment for Economically Disadvantaged Men Prostate Cancer Treatment for Economically Disadvantaged Men A Comparison of County Hospitals and Private Providers J. Kellogg Parsons, MD, MHS 1,2 ; Lorna Kwan, MPH 3 ; Sarah E. Connor, MPH 4 ; David

More information

Prognostic value of the Gleason score in prostate cancer

Prognostic value of the Gleason score in prostate cancer BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska

More information

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer 307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2

More information

The prognostic significance of percentage of tumour involvement according to disease risk group in men treated with radical prostatectomy

The prognostic significance of percentage of tumour involvement according to disease risk group in men treated with radical prostatectomy (2011) 13, 828 832 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE The prognostic significance of percentage of tumour involvement according to disease

More information

Detection & Risk Stratification for Early Stage Prostate Cancer

Detection & Risk Stratification for Early Stage Prostate Cancer Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:

More information

Accepted for publication 3 January 2005

Accepted for publication 3 January 2005 Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term

More information

Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy

Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with

More information

Original Article. Cancer September 15,

Original Article. Cancer September 15, Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

Results From the SEARCH Database

Results From the SEARCH Database Cigarette Smoking Is Associated With an Increased Risk of Biochemical Disease Recurrence, Metastasis, Castration- Resistant Prostate Cancer, and Mortality After Radical Prostatectomy Results From the SEARCH

More information

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and

More information

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer

Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy

More information

Research Article Higher Prostate Weight Is Inversely Associated with Gleason Score Upgrading in Radical Prostatectomy Specimens

Research Article Higher Prostate Weight Is Inversely Associated with Gleason Score Upgrading in Radical Prostatectomy Specimens Advances in Urology Volume 2013, Article ID 710421, 7 pages http://dx.doi.org/10.1155/2013/710421 Research Article Higher Prostate Weight Is Inversely Associated with Gleason Score Upgrading in Radical

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

Conceptual basis for active surveillance

Conceptual basis for active surveillance Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed

More information

A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy

A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy 1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD

More information

Active Surveillance (AS) is an expectant management. Health Services Research

Active Surveillance (AS) is an expectant management. Health Services Research Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer Health Services Research Jianyu Liu, Paul R. Womble, Selin Merdan, David C. Miller, James E. Montie, Brian T. Denton on

More information

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting

More information

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,

More information

When radical prostatectomy is not enough: The evolving role of postoperative

When radical prostatectomy is not enough: The evolving role of postoperative When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer

More information

Controversies in Prostate Cancer Screening

Controversies in Prostate Cancer Screening Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations

More information

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher

More information

Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties

Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.4 Urological Oncology Interval from Prostate Biopsy to RobotAssisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties

More information

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,

More information

Personalized Therapy for Prostate Cancer due to Genetic Testings

Personalized Therapy for Prostate Cancer due to Genetic Testings Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center

More information

Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy

Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

BJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent

BJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent 21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support

More information

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato

More information

Adam Raben M.D. Helen F Graham Cancer Center

Adam Raben M.D. Helen F Graham Cancer Center Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Gleason score = 8 prostate cancer: much more like Gleason score 9?

Gleason score = 8 prostate cancer: much more like Gleason score 9? 5 + 3 = 8 prostate cancer: much more like 9? Brandon A. Mahal, Vinayak Muralidhar*, Yu-Wei Chen, Toni K. Choueiri, Karen E. Hoffman, Jim C. Hu, Christopher J. Sweeney, James B. Yu**, Felix Y. Feng, Quoc-Dien

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. An Exploration of Risk Stratification for Active Surveillance and Androgen Deprivation Therapy Side Effects for Prostate Cancer Utilizing Data From the Surveillance, Epidemiology, and End Results Database

More information

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns. ; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect

More information

Journal of American Science 2018;14(1)

Journal of American Science 2018;14(1) Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,

More information

Radiation Therapy After Radical Prostatectomy

Radiation Therapy After Radical Prostatectomy Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg

More information

Nomograms for prostate cancer

Nomograms for prostate cancer Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large

More information

Aram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*

Aram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1* Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical

More information

The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy

The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy european urology 51 (2007) 940 948 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Natural History of Noncastrate Metastatic Prostate Cancer after Radical

More information

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,

More information

Corey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*

Corey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2* Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical

More information

Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes

Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes UROLCHI World J Urol DOI 10.1007/s00345-015-1515-6 ORIGINAL ARTICLE Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes Rodrigo A.

More information

Does the Time From Biopsy to Radical Prostatectomy Affect Gleason Score Upgrading in Patients With Clinical T1c Prostate Cancer?

Does the Time From Biopsy to Radical Prostatectomy Affect Gleason Score Upgrading in Patients With Clinical T1c Prostate Cancer? www.kjurology.org http://dx.doi.org/0.4/kju.204.55.6.395 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=0.4/kju.204.55.6.395&domain=pdf&date_stamp=204-06-6 Does the Time

More information

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan

More information

High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy

High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy Urological Oncology HGPIN AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER RP PIERORAZIO et al. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy

More information

Radical prostate surgery?

Radical prostate surgery? Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your

More information